Haleon plc Stock

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:10 2024-06-13 EDT 5-day change 1st Jan Change
325.8 GBX +1.56% Intraday chart for Haleon plc -0.61% +1.29%

Financials

Sales 2024 * 11.45B 14.61B 20.08B Sales 2025 * 11.94B 15.24B 20.94B Capitalization 29.3B 37.38B 51.37B
Net income 2024 * 1.49B 1.9B 2.61B Net income 2025 * 1.71B 2.18B 3B EV / Sales 2024 * 3.24 x
Net Debt 2024 * 7.82B 9.97B 13.71B Net Debt 2025 * 7.06B 9.01B 12.38B EV / Sales 2025 * 3.04 x
P/E ratio 2024 *
20.2 x
P/E ratio 2025 *
17.5 x
Employees 25,408
Yield 2024 *
1.9%
Yield 2025 *
2.19%
Free-Float 81.7%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.56%
1 week-0.61%
Current month+0.22%
1 month-0.61%
3 months-1.75%
6 months-0.52%
Current year+1.29%
More quotes
1 week
319.84
Extreme 319.8398
333.23
1 month
319.84
Extreme 319.8398
371.20
Current year
308.37
Extreme 308.3696
371.20
1 year
306.80
Extreme 306.8
371.20
3 years
241.17
Extreme 241.1735
371.20
5 years
241.17
Extreme 241.1735
371.20
10 years
241.17
Extreme 241.1735
371.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 21-07-21
Director of Finance/CFO 52 21-11-30
Chief Tech/Sci/R&D Officer - 21-12-15
Members of the board TitleAgeSince
Director/Board Member - 22-07-17
Director/Board Member 64 22-07-17
Director/Board Member 57 22-07-17
More insiders
Date Price Change Volume
24-06-13 325.8 +1.56% 10,404,790
24-06-12 320.8 -0.09% 36,720,090
24-06-11 321.1 -0.68% 18,583,510
24-06-10 323.3 -2.12% 14,788,230
24-06-07 330.3 -0.30% 10,097,480

Delayed Quote London S.E., June 13, 2024 at 11:35 am

More quotes
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.258 GBP
Average target price
3.646 GBP
Spread / Average Target
+11.92%
Consensus